BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Has Average Price Target of $35.00 According to Brokerages

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $35.00.

A number of equities research analysts have weighed in on the stock. Leerink Partners lifted their price target on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, September 21st. Wall Street Zen downgraded shares of BlossomHill Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating on shares of BlossomHill Therapeutics in a research report on Wednesday. Guggenheim upped their price target on BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Finally, Lifesci Capital assumed coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price target for the company.

Insider Activity

In other BlossomHill Therapeutics news, Director Orbimed Advisors Llc purchased 625,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bihua Chen purchased 312,500 shares of the business’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the director directly owned 3,614,034 shares of the company’s stock, valued at approximately $57,824,544. This trade represents a 9.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

BlossomHill Therapeutics Trading Up 5.9%

NASDAQ:BLSM opened at $19.69 on Friday. BlossomHill Therapeutics has a 52 week low of $15.25 and a 52 week high of $27.99. The company has a fifty day simple moving average of $19.89.

BlossomHill Therapeutics (NASDAQ:BLSM) last released its quarterly earnings results on Friday, September 18th. The company reported ($8.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). On average, research analysts predict that BlossomHill Therapeutics will post -5.54 EPS for the current fiscal year.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.